Figure 2: Treg markers are increased in both 1994 CDC and ICC CFS/ME patients. Monoclonal antibodies were used to examine the expression of CD4+, CD25+, CD127+, FOXP3+ Tregs and also the expression of CD39 and CD73 on Tregs in CFS/ME cases and non-fatigue controls. Data represents means ± SEM. * represents level of significance where P-values are less than 0.05 and the lines indicate significance between groups.